Pharsight

Braftovi is owned by Array Biopharma Inc.

Braftovi contains Encorafenib.

Braftovi has a total of 13 drug patents out of which 0 drug patents have expired.

Braftovi was authorised for market use on 27 June, 2018.

Braftovi is available in capsule;oral dosage forms.

Braftovi can be used as treatment of melanoma; braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy; braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda- approved test, indicated in combination with binimetinib for the treatment of melanoma with a braf mutation, braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy, treatment of melanoma, treatment of melanoma with a braf mutation; braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy; braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda- approved test, treatment of melanoma; braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda- approved test; braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy, treatment of melanoma mediated by a b-raf protein kinase; braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy; braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda- approved test.

Drug patent challenges can be filed against Braftovi from 2022-06-27.

The generics of Braftovi are possible to be released after 05 August, 2033.

^new

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8946250	ARRAY BIOPHARMA INC	3,4-diarylpyrazoles as protein kinase inhibitors	Jul, 2029 (6 years from now)
US8541575	ARRAY BIOPHARMA INC	3,4-diarylpyrazoles as protein kinase inhibitors	Feb, 2030 (6 years from now)
US8501758	ARRAY BIOPHARMA INC	Compounds and compositions as protein kinase inhibitors	Aug, 2030 (7 years from now)
US9593099	ARRAY BIOPHARMA INC	Compounds and compositions as protein kinase inhibitors	Aug, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9850230	ARRAY BIOPHARMA INC	Compounds and compositions as protein kinase inhibitors	Aug, 2030 (7 years from now)
US9850229	ARRAY BIOPHARMA INC	Compounds and compositions as protein kinase inhibitors	Aug, 2030 (7 years from now)
US9593100	ARRAY BIOPHARMA INC	Compounds and compositions as protein kinase inhibitors	Aug, 2030 (7 years from now)
US10005761	ARRAY BIOPHARMA INC	Compounds and compositions as protein kinase inhibitors	Aug, 2030 (7 years from now)
US9314464	ARRAY BIOPHARMA INC	Compounds and compositions as protein kinase inhibitors	Jul, 2031 (8 years from now)
US10258622	ARRAY BIOPHARMA INC	Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate	Nov, 2032 (9 years from now)
US9387208	ARRAY BIOPHARMA INC	Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate	Nov, 2032 (9 years from now)
US9763941	ARRAY BIOPHARMA INC	Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate	Nov, 2032 (9 years from now)
US9474754	ARRAY BIOPHARMA INC	Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitor	Aug, 2033 (10 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jun 27, 2023
Orphan Drug Exclusivity (ODE)	Jun 27, 2025
New Indication (I)	Apr 8, 2023

Drugs and Companies using ENCORAFENIB ingredient

NCE-1 date: 2022-06-27

Market Authorisation Date: 27 June, 2018

Treatment: Treatment of melanoma with a braf mutation; Braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a b...

Dosage: CAPSULE;ORAL